AT-62 ANALYSIS OF SURVIVAL CONCERNING THE EXTENT OF SURGICAL RESECTION IN NEW GLIOBLASTOMA MULTIFORME: A SINGLE-CENTRE RETROSPECTIVE AUDIT

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 16; no. suppl 5; p. v22
• Main Authors: Wright, J., Tresman, R., Dubois, C., Lewis, J., Surash, S.
• Format: Journal Article
• Language: English
• Published: 01-11-2014
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nou237.61

BACKGROUND: Within the literature there is a body of evidence which suggests greater cytoreductive surgery increases survival in patients with newly diagnosed glioblastoma multiforme (GBM). Complete surgical resection is not always possible and often only sub-total resection or biopsy is achieved. AIMS: We analysed survival of patients treated at our single neuro-oncology centre in the post-Stupp era regarding extent of surgical resection in relation to overall survival (OS). METHODS: Retrospective cohort sub-set analysis of the 90 patients newly diagnosed with GBM between December 2009 and December 2013, treated under Stupp combined modality protocol through a retrospective review of clinical records, comparing survival of patients who underwent biopsy, sub-total resection and complete resection. Survival data was calculated from date of diagnostic surgery. Survival analysis was completed for each subgroup using the Kaplan-Meier method. RESULTS: Whole cohort median OS was 14 months with a 40.9% 2-year survival rate. Biopsy group median OS was 9 months (18 patients; 20%). Subtotal resection (<90% tumour volume) group median OS was 12.5 months (24 patients; 26.67%). Complete resection (>90% tumour volume) group median OS was 15 months (48 patients; 53.33%). CONCLUSIONS: Patients undergoing complete resection have increased median OS compared to those undergoing less radical surgery. In patients unsuitable for radical surgery, biopsy or subtotal resection may provide a viable alternative alongside Stupp protocol. NOTE: further data of 25 patients to be analysed before finalisation.